Phase Ib Trial of Granulocyte-Macrophage Colony-Stimulating Factor Combined with Murine Monoclonal Antibody R24 in Patients with Metastatic Melanoma

Journal of Immunotherapy

Volumn 16, Issue 2, 1994, Pages 132-141

  Chachoua, Abraham ^a   Oratz, Ruth ^a   Liebes, Leonard ^a   Alter, Robert S ^a   Felice, Anthony ^a   Peace, Denise ^a   Vilcek, Jan ^a   Blum, Ronald H ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Combination therapy; Granulocyte macrophage colony stimulating factor; Metastatic melanoma; Murine monoclonal antibody R24; Phase Ib trial

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY R24;

ADULT; AGED; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG CYTOTOXICITY; EFFECTOR CELL; FATIGUE; FEMALE; FEVER; GRANULOCYTE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; MELANOMA; MONOCYTE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; URTICARIA; VOMITING;

ADULT; AGED; ANIMAL; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; GRANULOCYTES; HUMAN; MALE; MELANOMA; MICE; MIDDLE AGE; MONOCYTES; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028059136     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199408000-00007     Document Type: Article

References (30)

1. Grabstein KH, Urdal DL, Tushinski PJ, et al. Induction of macrophage tumoricidal activity by GM-CSF. Science 1986;232:506-8.
2. Cannistra SA, Rambaldi A, Spriggs DR, et al. Human gran-ulocyte-macrophage colony stimulating factor induces the expression of the tumor necrosis factor gene by the U937 cell line and by normal human monocytes. J Clin Invest 1987;79:1720-8.
3. Wang JM, Colella S, Allavena P, et al. Chemotactic activity of human recombinant granulocyte-macrophage colony stimulating factor. Immunology 1987;60:439-44.
4. Unanue ER, Allen PM. The basis for the immunoregulatory role of macrophages and other accessory cells. Science 1987;236:551-7.
5. Nathan CF. Secretory products of macrophages. J Clin Invest 1987;79:319-26.
6. Nathan CF, Brukner LH, Silverstein SC, Cohn ZA. Extracellular cytolysis by activated macrophages and granulo-cytes I. pharmacologic triggering of effector cells and release of hydrogen peroxide. J Exp Med 1979;149:84-99.
7. Nathan CF, Murray HW, Cohn ZA. The macrophage as an effector cell. N Engl J Med 1980;303:622-6.
8. Nossal GVJ. The basic components of the immune system. N Engl J Med 1987;316:1320-5.
9. Metcalf D. The molecular biology and function of the gran-ulocyte macrophage colony stimulating factors. Blood 1986;67:257-67.
10. Kurkland JL, Brockman RS, Broxmeyer HE, Moore MA. Limitation of excessive myelopoiesis by the intrinsic modulation of macrophage derived prostaglandin E. Science 1978;199:552-5.
11. Kurkland JL, Pelus LM, Ralph P, et al. Induction of PGE synthesis in normal and neoplastic macrophages: role of CSF(S) distinct from effects on myeloid progenitor proliferation. Proc Natl Acad Sci USA 1979;76:2327-30.
12. Handman E, Burgess A. Stimulation by GM-CSF of Leish-mania tropica killing by macrophages. J Immunol 1979;122:1134-7.
13. Wing EJ, Waheed A, Shadduck R, et al. Effect of CSF on murine macrophages. J Clin Invest 1982;69:270-6.
14. Wing EJ, Magee DM, Whiteside TL, et al. Recombinant human granulocyte/macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor alpha and interferon in cancer patients. Blood 1989;73:643-6.
15. Lieveld JL, Frediani KE, Winslow JM, et al. Cytokine effects and role of adhesive proteins and FC receptors in human macrophage-mediated antibody dependent cellular cytotoxicity. J Cell Biochem 1991;45:381-90.
16. Kushner BH, Cheung NK. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood 1989;73:1936-41.
17. Chachoua A, Oratz R, Hoogmoed R, et al. Monocyte activation following systemic administration of granulocyte-macrophage colony stimulating factor. J Immunother 1994;15:217-24.
18. Steis RG, VanderMolen LA, Longo DL, et al. Recombinant human granulocyte-macrophage colony stimulating factor in patients with advanced malignancy: a phase Ib trial. J Natl Cancer Inst 1990;82:697-703.
19. Vogel CW, Welt SW, Carswell EA, et al. A murine IgG monoclonal antibody to a melanoma antigen that activates human complement in vitro and in vivo. Immunobiology 1983;164:309-13.
20. Knuth A. Response to monoclonal antibodies in melanoma: specific or non-specific. Eur J Cancer Clin Oncol 1986;22:1285-8.
21. Cheresh D, Honsik CJ, Staffileno LK, et al. Disialoganglio-side CD3 on antibody mediated tumor cytolysis. Proc Natl Acad Sci USA 1985;82:5155-9.
22. Vadhan-Raj S, Cordon-Cardo C, Carswell E, et al. Phase I trial of a mouse monoclonal antibody against CD3 ganglioside in patients with metastatic melanoma. J Clin Oncol 1988;6:1636-48.
23. Liebes L, Walsh CM, Chachoua A, et al. Modulation of monocyte function by muramyl tripeptide phosphatidyleth-anolamine in a phase II study in patients with metastatic melanoma. J Natl Cancer Inst 1992;84:694-9.
24. Weersink AJL, van Kessel KPM, van den Tol ME, et al. Human granulocytes express a 55-kDa lipopolysaccharide-binding protein on the cell surface that is identical to the bactericidal/permeability-increasing protein. J Immunol 1993;150:253-63.
25. Liesveld JL, Abboud CN, Looney RJ, et al. Expression of IgG Fc receptors in myeloid leukemic cell lines. Effect of colony-stimulating factors and cytokines. J Immunol 1988;140:1527-33.
26. Munn DH, Cheung N-KV. Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. Induction of efficient antibody-mediated antitumor cytotoxicity not detected by isotope release assays. J Exp Med 1989;170:511-26.
27. Raymond J, Kirkwood J, Vlock D, et al. A phase Ib trial of murine monoclonal antibody R24 (Anti GD3) in metastatic melanoma. Proc Am. Soc Clin Oncol 1991;10:1045.
28. Bajorin DF, Chapman PB, Wong G, et al. Phase I evaluation pf a combination of monoclonal antibody R24 and interleu-kin 2 in patients with metastatic melanoma. Cancer Res 1990;50:7490-5.
29. Creekmore S, Urba W, Kopp W, et al. Phase Ib/II trial of R24 antibody and interleukin 2 in melanoma. Proc Am Soc Clin Oncol 1992;11:1186.
30. Steffens TA, Bajorin DF, Williams LJ, et al. A phase I trial of monoclonal antibody R24 and recombinant human macrophage colony stimulating factor (rhM-CSF) in patients with advanced melanoma. Proc Am Soc Clin Oncol 1992;11:1182.